Showing results (1401-1410 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 2, 2021
Network pharmacology of triptolide in cancer cells: implications for transcription factor bindingEan-Jeong Seo, Mona Dawood, Annika K Hult, et al.
Investigational New Drugs|January 1, 1985
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancerJ C Allegra, T Woodcock, S Woolf, et al.
Investigational New Drugs|January 1, 1986
Phase II trial of 10 deaza-aminopterin in patients with bladder cancerT Ahmed, A Yagoda, H I Scher, et al.
Investigational New Drugs|July 29, 2021
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinomaGrégoire Marret, Nicolas Isambert, Keyvan Rezai, et al.
Investigational New Drugs|April 17, 2013
Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumorsS Tjulandin, V Moiseyenko, V Semiglazov, et al.
Investigational New Drugs|March 20, 2013
Novel bourgeonal fragrance conjugates for the detection of prostate cancerAlexander Sturzu, Sumbla Sheikh, Hartmut Echner, et al.
Investigational New Drugs|April 5, 2013
A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancerBalazs Halmos, Yuxia Jia, Joseph A Bokar, et al.
Investigational New Drugs|May 7, 2013
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)Suzanne Richter, Philippe L Bedard, Eric Xueyu Chen, et al.
Investigational New Drugs|May 21, 2013
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypesJulie C Friedland, Donald L Smith, Jim Sang, et al.
Investigational New Drugs|February 26, 2013
A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancerRobert Dreicer, Jorge Garcia, Brian Rini, et al.
Pageof 372